BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates.

Key contributors included LEQEMBI with a 28.1 billion yen increase, Lenvima with 24.9 billion yen growth, and Dayvigo up by 9.3 billion yen. Naito emphasized significant milestones for LEQEMBI ...

The FDA has started its review of a subcutaneous injection formulation of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to receive maintenance doses at home, rather than in ...

Their doctor places them both on Leqembi, recently approved by the FDA for use in men and women with early-stage Alzheimer’s. The husband has a positive cognitive response to Leqembi ...

Dodge has been inexplicably steadfast in its push toward an electrified future, but recent comments from CEO Matt McAlear suggest the brand is considering dropping a V8 in the new Charger.

Eisai’s Biogen-partnered Alzheimer’s therapy Leqembi is “on track” to meet a fiscal year 2024 revenue goal of ¥42.5 billion ($279 million)—despite U.S. sales continuing to drag. In the third quarter ...